Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

P53 and the proteasome regulate androgen receptor activity.

Guseva NV, Rokhlin OW, Glover RA, Cohen MB.

Cancer Biol Ther. 2012 May;13(7):553-8. doi: 10.4161/cbt.19605. Epub 2012 May 1.

PMID:
22407029
2.

Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor.

Guseva NV, Rokhlin OW, Bair TB, Glover RB, Cohen MB.

Oncotarget. 2012 Feb;3(2):183-94.

3.

Caspase-2-Based Regulation of the Androgen Receptor and Cell Cycle in the Prostate Cancer Cell Line LNCaP.

Taghiyev AF, Rokhlin OW, Glover RB.

Genes Cancer. 2011 Jul;2(7):745-52. doi: 10.1177/1947601911426007.

4.

TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status.

Guseva NV, Rokhlin OW, Glover RA, Cohen MB.

Cancer Biol Ther. 2011 Jul 1;12(1):80-5. doi: 10.4161/cbt.12.1.15721. Epub 2011 Jul 1.

PMID:
21525791
5.

KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer.

Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB.

Cancer Biol Ther. 2010 Feb;9(3):224-35. Epub 2010 Feb 25.

PMID:
20023417
6.

Mechanisms of prostate cancer cell survival after inhibition of AR expression.

Cohen MB, Rokhlin OW.

J Cell Biochem. 2009 Feb 15;106(3):363-71. doi: 10.1002/jcb.22022. Review.

PMID:
19115258
7.

Functional genetic screening reveals the role of mitochondrial cytochrome b as a mediator of FAS-induced apoptosis.

Komarov AP, Rokhlin OW, Yu CA, Gudkov AV.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14453-8. doi: 10.1073/pnas.0807549105. Epub 2008 Sep 16.

8.

Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.

Sawant RM, Cohen MB, Torchilin VP, Rokhlin OW.

J Drug Target. 2008 Aug;16(7):601-4. doi: 10.1080/10611860802228954.

PMID:
18686131
9.

MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer.

Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB.

Cancer Biol Ther. 2008 Aug;7(8):1288-96. Epub 2008 Aug 13.

PMID:
18497571
10.

Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy.

Svensson RU, Barnes JM, Rokhlin OW, Cohen MB, Henry MD.

Cancer Res. 2007 Nov 1;67(21):10445-54.

11.

Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).

Guseva NV, Rokhlin OW, Taghiyev AF, Cohen MB.

Breast Cancer Res Treat. 2008 Feb;107(3):349-57. Epub 2007 Apr 24.

PMID:
17453339
12.

Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival.

Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA, Cohen MB.

Cancer Biol Ther. 2007 May;6(5):732-42. Epub 2007 Feb 5.

PMID:
17387273
13.

TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome.

Taghiyev AF, Guseva NV, Glover RA, Rokhlin OW, Cohen MB.

Cancer Biol Ther. 2006 Sep;5(9):1199-205. Epub 2006 Sep 9.

PMID:
17110788
14.

Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.

Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG, Cohen MB.

Mol Cancer Res. 2006 Feb;4(2):113-23.

15.

Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP.

Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, Cohen MB.

Oncogene. 2005 Oct 13;24(45):6773-84.

16.

Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment.

Taghiyev AF, Guseva NV, Sturm MT, Rokhlin OW, Cohen MB.

Cancer Biol Ther. 2005 Apr;4(4):382-90. Epub 2005 Apr 21.

PMID:
15846101
17.

p53 is a suppressor of inflammatory response in mice.

Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, Nedospasov SA, Hazen SL, Feinstein E, Gudkov AV.

FASEB J. 2005 Jun;19(8):1030-2. Epub 2005 Apr 5.

PMID:
15811878
18.
19.

Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines.

Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB.

Cancer Biol Ther. 2004 Aug;3(8):761-8. Epub 2004 Aug 12.

PMID:
15197350
20.

Death receptor-induced cell death in prostate cancer.

Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB.

J Cell Biochem. 2004 Jan 1;91(1):70-99. Review.

PMID:
14689583
22.

Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.

Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, Gudkov AV.

Cancer Res. 2003 Jun 1;63(11):2905-12.

23.
24.

TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP.

Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrbu SI, Cohen MB.

Cancer Biol Ther. 2002 Nov-Dec;1(6):631-7.

PMID:
12642685
25.

Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription.

Rokhlin OW, Glover RA, Taghiyev AF, Guseva NV, Seftor RE, Shyshynova I, Gudkov AV, Cohen MB.

J Biol Chem. 2002 Sep 6;277(36):33213-9. Epub 2002 Jun 28.

27.

Contribution of death receptor and mitochondrial pathways to Fas-mediated apoptosis in the prostatic carcinoma cell line PC3.

Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB.

Prostate. 2002 Jun 1;51(4):231-40.

PMID:
11987151
28.

Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis.

Rokhlin OW, Guseva N, Tagiyev A, Knudson CM, Cohen MB.

Oncogene. 2001 May 17;20(22):2836-43.

30.

Cytochrome c is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines.

Gewies A, Rokhlin OW, Cohen MB.

Cancer Res. 2000 Apr 15;60(8):2163-8.

31.

p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP.

Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS, Cohen MB.

Oncogene. 2000 Apr 6;19(15):1959-68.

32.
33.

5E10: a prostate-specific surface-reactive monoclonal antibody.

Rokhlin OW, Weiner GJ, Cohen MB.

Cancer Lett. 1998 Sep 25;131(2):129-36.

PMID:
9851244
34.

Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53.

Komarova EA, Diatchenko L, Rokhlin OW, Hill JE, Wang ZJ, Krivokrysenko VI, Feinstein E, Gudkov AV.

Oncogene. 1998 Sep 3;17(9):1089-96.

35.

Dominant nature of the resistance to Fas- and tumor necrosis factor-alpha-mediated apoptosis in human prostatic carcinoma cell lines.

Rokhlin OW, Hostager BS, Bishop GA, Sidorenko SP, Glover RA, Gudkov AV, Cohen MB.

Cancer Res. 1997 Sep 15;57(18):3941-3.

36.

Fas-mediated apoptosis in human prostatic carcinoma cell lines.

Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB.

Cancer Res. 1997 May 1;57(9):1758-68.

37.

Cellular adhesion molecules in urologic malignancies.

Cohen MB, Griebling TL, Ahaghotu CA, Rokhlin OW, Ross JS.

Am J Clin Pathol. 1997 Jan;107(1):56-63. Review.

PMID:
8980368
38.
39.

Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface.

Rokhlin OW, Griebling TL, Karassina NV, Raines MA, Cohen MB.

Anticancer Res. 1996 Mar-Apr;16(2):557-63.

PMID:
8687098
40.

Expression of CD44 isoforms in human prostate tumor cell lines.

Stevens JW, Palechek PL, Griebling TL, Midura RJ, Rokhlin OW, Cohen MB.

Prostate. 1996 Mar;28(3):153-61.

PMID:
8628718
41.
42.

Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow.

Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD.

J Immunol. 1995 May 1;154(9):4456-65.

PMID:
7722302
43.

Expression of cellular adhesion molecules on human prostate tumor cell lines.

Rokhlin OW, Cohen MB.

Prostate. 1995 Apr;26(4):205-12.

PMID:
7536326

Supplemental Content

Loading ...
Support Center